Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 12/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15457806 | 0.84 | TP53 (0.47) | TP53DPP4CCR1ALDH1A1DPP7 | |
| SCHEMBL8356758 | 0.83 | TP53 (0.49) | TP53DPP4CCR1CA12CA1 | |
| SCHEMBL9099990 | 0.82 | AAK1 (0.40) | CA1CA2AAK1 | |
| SCHEMBL9099994 | 0.82 | AAK1 (0.40) | CA1CA2AAK1 | |
| SCHEMBL15457807 | 0.81 | DPP4 (0.49) | TP53DPP4CCR1DPP7 | |
| SCHEMBL18596306 | 0.79 | DPP4 (0.43) | TP53DPP4DPP7 | |
| SCHEMBL15458248 | 0.79 | DPP4 (0.43) | TP53DPP4DPP7 | |
| SCHEMBL240589 | 0.76 | MMP2 (0.42) | TP53CA12CA1CA2MMP2 | |
| SCHEMBL5988909 | 0.76 | MMP2 (0.40) | TP53CA12CA1CA2MMP2 | |
| SCHEMBL12654802 | 0.76 | MMP2 (0.40) | TP53CA12CA1CA2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2013-06-06 | — | — | US | disclosed |
| US-8361998-B2 | Compounds and their use as IKACh blockers | ASTRAZENECA AB | 2013-01-29 | — | — | US | disclosed |
| WO-2012074469-A1 | NEW IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | TP53 3570/4885DPP4 4071/4885CCR1 3647/4885 |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | TP53 3570/4885DPP4 4071/4885CCR1 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.